KRAS is a pivotal oncogene within the RAS family, encoding a small GTPase that plays a central role in regulating cell proliferation, survival, and differentiation. Mutations in KRAS—such as G12D, G12V, and G12—result in a constitutively active GTP-bound state, driving oncogenesis in approximately 20% of human cancers, including pancreatic, colorectal, and non-small cell lung cancer. Historically, drug development targeting KRAS has been challenging due to the absence of a well-defined binding pocket on its protein surface. However, recent advances have introduced molecular glues as a promising new class of therapeutic agents capable of modulating previously undruggable targets.
We value your inquiries and are here to provide you with tailored solutions for your drug discovery and development needs. Whether you have questions, require more information, or are interested in discussing potential collaborations, our team of experts is just a message away.
Feel free to reach out to us.
Address: Bldg 16, Yd 18, Kechuang 13th St, Etown, Tongzhou Dist, Beijing, 100176, China
Email: marketing@ice-biosci.com
Tel：+86-10-67809840
Get a quote
Go top
